Amarillo Biosciences (AMARD) 0.4000 $AMARD Amar
Post# of 273242
Posted On: 09/14/2016 3:01:48 AM
Amarillo Biosciences (AMARD) 0.4000 $AMARD
Amarillo Biosciences, Inc. Summarizes New Plan of Operation
Marketwired - Mon May 18, 8:30AM CDT
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) (OTCQB: AMAR) today summarized its new operating plan following the Company's emergence from Chapter 11 Bankruptcy. ABI disclosed that it had arisen from bankruptcy January 23, 2015, when the Final Decree closing the case had been signed by Judge Robert L. Jones of the United States Bankruptcy Court for the Northern District of Texas in Case No. 13-20393-RJL-11.
Oral Proteins and Peptides Market, 2015 - 2025
M2 - Wed Feb 18, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/g33dxb/oral_proteins_and) has announced the addition of the "Oral Proteins and Peptides Market, 2015 - 2025" report to their offering. The Oral Proteins and Peptides Market (2nd edition), 2015-2025 report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. Highlights: - The market is characterized by the presence of 76 molecules in different phases of development.Four molecules are in the late stage clinical trials (phase III); of these, Oral Octreolin, Ostora and Plecanatide are likely to be made commercially available in 2016. - Diabetes stands out among the indication groups for which various molecules are in investigational studies. Nearly 37% of the total molecules under research are being developed for diabetic disorders. Other prominent areas include gastric disorders andbone diseases. - The market is not dominated by the presence of a big company or a group of companies. Several start-ups have led research efforts by developing the technologies that facilitate oral formulation of proteins and peptides. - Prominent technologies include Axcess, GIPET, Peptelligence and Disulfide Rich Peptides; a number of oral proteins and peptides are based on one of these technologies. - One of the primary drivers for growth in the industry is the rising venture capital interest and available funding from other avenues. In total, over the last 10 years, we identified total investment of close to USD 0.9 billion. - The current crop of oral proteins and peptides is likely to benefit from early success of Linzess; combined, we expect it to be a multi-billion dollar market growing at an annualised rate of 30% over the coming decade. Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. OVERVIEW AND MARKET BACKGROUND 5. DRUG PROFILES AND MARKET FORECAST 6. CASE STUDIES: LIPROTAMASE, SANDIMMUNE, DDAVP 7. TECHNOLOGY PLATFORMS 8. RECENT PARTNERSHIPS 9. VENTURE CAPITAL SUPPORT 10. SWOT ANALYSIS 11. CONCLUSION 12. APPENDIX 1: Tabulated Data 13. APPENDIX 2: List of Companies Companies Mentioned Following companies have been mentioned in the report: 30 of the 100 Companies Featured - Abbott Laboratories - AbbVie - Affilogic - AIMM Therapeutics - Alchemia - Almirall S.A. - Alnara Pharmaceuticals - Amarillo Biosciences - Anthera Pharmaceuticals - Apollo Life Sciences - Apotex - Aptalis Pharma - Arisgen - Armour - Astellas - AstraZeneca - Avaxia Biologics - Barr Pharmaceuticals - Biocon - Biodel Inc. - Bone Medical - Bristol-Myers Squibb - Cara Therapeutics - Centocor Ortho - Chiasma Pharmaceuticals - Clinigene - Cosmo Pharmaceuticals - Diabetology Ltd. - Diasome Pharma - Digestive Care Inc. Following Universities / Research Centres have been mentioned in this report: - Elan Biotechnology Research Centre, Trinity College, - Biomedical Advanced Research and Development Agency - BioScience Innovation Centre - Hadassit Medical Research - Tianjin International Joint Academy of Biomedicine - University of Southern California - National Institute of Health Following Venture Capital firms have been mentioned in this report: 30 of the 50 Plus Firms - 7 Med Health Ventures - Abingworth - Aegis Capital Corporation - Alta Biopharma Partners - ARCH Venture Partners - Ariel Southeast Angel Partners - Ascent Biomedical Ventures - Beacon Angels - Boston Harbor Angels - Cherrystone Angels - Connecticut Innovations - CT Innovations - Devon Park BioVentures - DNA Biomedical Solutions Ltd. - F2 Ventures - F3 Ventures - Foresite Capital - Fredric Price - GGV Capital - Golden Seeds - Google Ventures - Granite State Angels - Great Point Partners - Healthcare Private Equity - InCubeBioVentures - Jerusalem Global Ventures - Johnson and Johnson Development Corporation - LaunchPad Venture Group - Life Sciences Fund Amsterdam - Lilly Ventures For more information visit http://www.researchandmarkets.com/research/g3...oteins_and
JNJ: 117.61 (-1.55), ABT: 40.64 (-0.78), ANTH: 3.12 (-0.07), BMY: 55.60 (-0.72), BIOD: 0.41 (unch)
Drug Delivery Partnering Terms and Agreements 2015
M2 - Mon Feb 16, 10:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpgmrs/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The drug delivery technology includes the following sub-technology areas: - Bioavailability - Implanatable - Oral delivery - Rapid release - Delayed release - Parenteral - Infusion - Injectable - Pro-drug - Targeted - Tropical - Transdermal - Buccal - Inhaled - Nasal - Ocular - Rectal - Sublingual - Urogenital Companies Mentioned: 30 of the 350 Companies that Feature in this Extensive Report - 3M - 3M Drug Delivery Systems - AAIPharma Services - Abbott - Accredo Health Group - Acelrx Pharmaceuticals - Acorda Therapeutics - Actavis - Actelion - Actient Pharmaceuticals - Adeona Pharmaceuticals - Adolor - Alchemia - Aldexa Therapeutics - Alexza Pharmaceuticals - Alfacell - Alimera Sciences - Alkermes - Allergan - Allos Therapeutics - Amag Pharmaceuticals - AMAG Pharmaceuticals - Amarillo Biosciences - Amarin - Amicus Therapeutics - Ampio Pharmaceuticals - Amylin Pharmaceuticals - Anesiva - Angiotech Pharmaceuticals - AP Pharma For more information visit http://www.researchandmarkets.com/research/rp...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AMPE: 0.86 (-0.04), ACOR: 24.87 (-0.07), ALKS: 47.16 (-0.58), AGN: 240.10 (-0.13), ALDX: 5.62 (+0.09), ALIM: 1.49 (-0.02), AMAG: 23.35 (+0.14), FOLD: 6.78 (-0.19)
Amarillo Biosciences, Inc. Reorganizes, Exits Bankruptcy, and Opens a New Chapter in the Healthcare Industry
ACCESSWIRE - Mon Feb 02, 8:16AM CST
AMARILLO, TX / ACCESWIRE / February 2, 2015 / Amarillo Biosciences, Inc. (ABI) (OTC Pink: AMAR) (PINKSHEETS: AMAR), today announced that the Company has completely reorganized and emerged from the voluntary Chapter 11 Bankruptcy declared fifteen months ago. The Order and Final Decree closing the case was signed by Judge Robert L. Jones of the Northern District of Texas, on January 23, 2015.
Amarillo Biosciences, Inc. Summarizes New Plan of Operation
Marketwired - Mon May 18, 8:30AM CDT
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) (OTCQB: AMAR) today summarized its new operating plan following the Company's emergence from Chapter 11 Bankruptcy. ABI disclosed that it had arisen from bankruptcy January 23, 2015, when the Final Decree closing the case had been signed by Judge Robert L. Jones of the United States Bankruptcy Court for the Northern District of Texas in Case No. 13-20393-RJL-11.
Oral Proteins and Peptides Market, 2015 - 2025
M2 - Wed Feb 18, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/g33dxb/oral_proteins_and) has announced the addition of the "Oral Proteins and Peptides Market, 2015 - 2025" report to their offering. The Oral Proteins and Peptides Market (2nd edition), 2015-2025 report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. Highlights: - The market is characterized by the presence of 76 molecules in different phases of development.Four molecules are in the late stage clinical trials (phase III); of these, Oral Octreolin, Ostora and Plecanatide are likely to be made commercially available in 2016. - Diabetes stands out among the indication groups for which various molecules are in investigational studies. Nearly 37% of the total molecules under research are being developed for diabetic disorders. Other prominent areas include gastric disorders andbone diseases. - The market is not dominated by the presence of a big company or a group of companies. Several start-ups have led research efforts by developing the technologies that facilitate oral formulation of proteins and peptides. - Prominent technologies include Axcess, GIPET, Peptelligence and Disulfide Rich Peptides; a number of oral proteins and peptides are based on one of these technologies. - One of the primary drivers for growth in the industry is the rising venture capital interest and available funding from other avenues. In total, over the last 10 years, we identified total investment of close to USD 0.9 billion. - The current crop of oral proteins and peptides is likely to benefit from early success of Linzess; combined, we expect it to be a multi-billion dollar market growing at an annualised rate of 30% over the coming decade. Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. OVERVIEW AND MARKET BACKGROUND 5. DRUG PROFILES AND MARKET FORECAST 6. CASE STUDIES: LIPROTAMASE, SANDIMMUNE, DDAVP 7. TECHNOLOGY PLATFORMS 8. RECENT PARTNERSHIPS 9. VENTURE CAPITAL SUPPORT 10. SWOT ANALYSIS 11. CONCLUSION 12. APPENDIX 1: Tabulated Data 13. APPENDIX 2: List of Companies Companies Mentioned Following companies have been mentioned in the report: 30 of the 100 Companies Featured - Abbott Laboratories - AbbVie - Affilogic - AIMM Therapeutics - Alchemia - Almirall S.A. - Alnara Pharmaceuticals - Amarillo Biosciences - Anthera Pharmaceuticals - Apollo Life Sciences - Apotex - Aptalis Pharma - Arisgen - Armour - Astellas - AstraZeneca - Avaxia Biologics - Barr Pharmaceuticals - Biocon - Biodel Inc. - Bone Medical - Bristol-Myers Squibb - Cara Therapeutics - Centocor Ortho - Chiasma Pharmaceuticals - Clinigene - Cosmo Pharmaceuticals - Diabetology Ltd. - Diasome Pharma - Digestive Care Inc. Following Universities / Research Centres have been mentioned in this report: - Elan Biotechnology Research Centre, Trinity College, - Biomedical Advanced Research and Development Agency - BioScience Innovation Centre - Hadassit Medical Research - Tianjin International Joint Academy of Biomedicine - University of Southern California - National Institute of Health Following Venture Capital firms have been mentioned in this report: 30 of the 50 Plus Firms - 7 Med Health Ventures - Abingworth - Aegis Capital Corporation - Alta Biopharma Partners - ARCH Venture Partners - Ariel Southeast Angel Partners - Ascent Biomedical Ventures - Beacon Angels - Boston Harbor Angels - Cherrystone Angels - Connecticut Innovations - CT Innovations - Devon Park BioVentures - DNA Biomedical Solutions Ltd. - F2 Ventures - F3 Ventures - Foresite Capital - Fredric Price - GGV Capital - Golden Seeds - Google Ventures - Granite State Angels - Great Point Partners - Healthcare Private Equity - InCubeBioVentures - Jerusalem Global Ventures - Johnson and Johnson Development Corporation - LaunchPad Venture Group - Life Sciences Fund Amsterdam - Lilly Ventures For more information visit http://www.researchandmarkets.com/research/g3...oteins_and
JNJ: 117.61 (-1.55), ABT: 40.64 (-0.78), ANTH: 3.12 (-0.07), BMY: 55.60 (-0.72), BIOD: 0.41 (unch)
Drug Delivery Partnering Terms and Agreements 2015
M2 - Mon Feb 16, 10:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpgmrs/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The drug delivery technology includes the following sub-technology areas: - Bioavailability - Implanatable - Oral delivery - Rapid release - Delayed release - Parenteral - Infusion - Injectable - Pro-drug - Targeted - Tropical - Transdermal - Buccal - Inhaled - Nasal - Ocular - Rectal - Sublingual - Urogenital Companies Mentioned: 30 of the 350 Companies that Feature in this Extensive Report - 3M - 3M Drug Delivery Systems - AAIPharma Services - Abbott - Accredo Health Group - Acelrx Pharmaceuticals - Acorda Therapeutics - Actavis - Actelion - Actient Pharmaceuticals - Adeona Pharmaceuticals - Adolor - Alchemia - Aldexa Therapeutics - Alexza Pharmaceuticals - Alfacell - Alimera Sciences - Alkermes - Allergan - Allos Therapeutics - Amag Pharmaceuticals - AMAG Pharmaceuticals - Amarillo Biosciences - Amarin - Amicus Therapeutics - Ampio Pharmaceuticals - Amylin Pharmaceuticals - Anesiva - Angiotech Pharmaceuticals - AP Pharma For more information visit http://www.researchandmarkets.com/research/rp...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AMPE: 0.86 (-0.04), ACOR: 24.87 (-0.07), ALKS: 47.16 (-0.58), AGN: 240.10 (-0.13), ALDX: 5.62 (+0.09), ALIM: 1.49 (-0.02), AMAG: 23.35 (+0.14), FOLD: 6.78 (-0.19)
Amarillo Biosciences, Inc. Reorganizes, Exits Bankruptcy, and Opens a New Chapter in the Healthcare Industry
ACCESSWIRE - Mon Feb 02, 8:16AM CST
AMARILLO, TX / ACCESWIRE / February 2, 2015 / Amarillo Biosciences, Inc. (ABI) (OTC Pink: AMAR) (PINKSHEETS: AMAR), today announced that the Company has completely reorganized and emerged from the voluntary Chapter 11 Bankruptcy declared fifteen months ago. The Order and Final Decree closing the case was signed by Judge Robert L. Jones of the Northern District of Texas, on January 23, 2015.
(0)
(0)Scroll down for more posts ▼